Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival

Cancer Biotherapy & Radiopharmaceuticals
Robert O DillmanShankar K Nayak

Abstract

We established short-term cultures of pure tumor cells for use as autologous tumor cell vaccines in an effort to study the effects of patients-specific immunotherapy. Surgically resected fresh tumor was obtained from patients with metastatic cancer. Successful tumor cell lines (5 x 10(7)) were expanded to 10(8) cells, irradiated, and cryopreserved for clinical use. Following a baseline test of delayed-type hypersensitivity (DTH) to an i.d. injection of 10(6) irradiated autologous tumor cells, patients received 3 weekly s.c. injections of 10(7) cells, had a repeat DTH test at week-4, then received monthly vaccinations for 5 months. A positive DTH test was defined as > or = 10 mm induration; survival was determined from the first DTH test. Short-term cell lines were successfully established for 299/695 patients (43%). Vaccines were prepared for 231 patients, 142 of whom were treated, and 125 had a baseline DTH test recorded. Median follow up at the time of analysis was greater than 5 years. There was no difference in survival for any of the following: gender, age > 50 years, melanoma histology, anergy to common recall antigens or baseline DTH test result. Only 17 patients had a positive DTH at baseline (14%), but DTH converted fr...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S MitchellL Stevenson
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D BerdM J Mastrangelo
Oct 14, 1993·The New England Journal of Medicine·D A KesslerJ Woodcock
Jul 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·R O DillmanL Beutel
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H C HooverM G Hanna
Jan 1, 1997·Journal of Immunotherapy·M L Salgaller
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·R O DillmanL D Beutel
Jun 14, 2000·Cancer Biotherapy & Radiopharmaceuticals·R K Oldham

❮ Previous
Next ❯

Citations

Apr 27, 2011·Cancer Immunology, Immunotherapy : CII·Nicolás AmianoH Eduardo Chuluyan
Aug 23, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yingjuan Lu, Philip S Low
Jan 15, 2005·Cancer Biotherapy & Radiopharmaceuticals·Robert DillmanShankar Nayak
Jan 15, 2005·Cancer Biotherapy & Radiopharmaceuticals·Robert DillmanShankar Nayak
Aug 24, 2005·Cancer Biotherapy & Radiopharmaceuticals·Robert O DillmanPatric Schiltz
Sep 21, 2010·Cancer Biotherapy & Radiopharmaceuticals·Robert O DillmanCarol DePriest
Aug 5, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O DillmanCarol DePriest
Sep 1, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Mark B Faries, Donald L Morton
Feb 21, 2007·Expert Opinion on Biological Therapy·Adam I RikerHung T Khong
Apr 10, 2009·Cancer Investigation·Karen S Anderson
Apr 4, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jonathan D Powell
Nov 3, 2004·Vaccine·John R Yannelli, Joanne M Wroblewski
Nov 4, 2016·Human Vaccines & Immunotherapeutics·Robert O Dillman
Oct 7, 2004·The Prostate·Senthamil R SelvanRobert O Dillman
Apr 7, 2020·Current Pharmaceutical Design·Qi TangHanmei Li
Aug 17, 2005·Cancer Investigation·Saji Eapen, Janice P Dutcher
Apr 17, 2018·Current Surgery Reports·Austin D WilliamsJulia Tchou
Feb 1, 2006·Personalized Medicine·Mike WhelanAngus Dalgleish

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.